The Food and Drug Administration on Wednesday approved Gilead's twice-yearly antiviral injection for preventing HIV — a milestone that the company and some experts say could help bring the world ...
The FDA has approved lenacapvir, a twice-yearly injection to prevent HIV infection that could improve adherence rates compared to other PrEP medications. The drug, which will be sold under the brand ...
Share on Pinterest Lenacapavir is a twice-yearly injection to prevent HIV that could improve adherence rates compared to other PrEP medications. d3sign/Getty Images The WHO issued a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback